VONOFAST® (Vonoprazan) Film-Coated Tablets
Pharmacological Class: Potassium-Competitive Acid Blocker (P-CAB)
More Than 9.5k Happy patients are using VONOFAST®
What is Vonofast?
VONOFast is a next-generation gastric acid suppressant belonging to the Potassium-Competitive Acid Blocker (P-CAB) class. Unlike conventional Proton Pump Inhibitors (PPIs), vonoprazan does not require acid activation and provides rapid, potent, and sustained suppression of gastric acid secretion.
How Vonofast Works
Vonoprazan competitively and reversibly inhibits potassium binding to gastric H+,K+-ATPase (the gastric proton pump) inside parietal cells. Due to its strong basicity, resulting in:
- Rapid onset of acid suppression from Day 1.
- Potent reduction of gastric acid secretion.
- Enhanced intragastric pH maintenance.
Acid Suppression Performance
Following administration of vonoprazan for 7 consecutive days:
- Vonofast 10 mg maintains an intragastric pH ≥4 for approximately 63% of a 24-hour period.
- Vonofast 20 mg maintains an intragastric pH ≥4 for approximately 83% of a 24-hour period.
Vonoprazan competitively and reversibly inhibits potassium binding to gastric H+,K+-ATPase (the gastric proton pump) inside parietal cells. Due to its strong basicity, vonoprazan accumulates within gastric parietal cells
(Note: While it provides rapid acid suppression from Day 1, any long-term use beyond these timeframes is reserved for maintaining healed reflux or preventing ulcer recurrence in chronic NSAID/aspirin users.)
10/20mg
Concentrations
Film-Coated Vonoprazan Tablets Available Strengths: 10 mg & 20 mg
Gastric Malignancy: Symptomatic response to Vonofast therapy does not preclude the presence of gastric malignancy. Gastric cancer should be ruled out before initiating treatment where clinically indicated
Fast Acid Suppression:
Immediate activity from Day 1 without the need for acid activation.
Powerful and Prolonged Acid Control:
Maintains target intragastric pH levels for prolonged periods.
Long Duration of Action:
Formulated for continuous day and night coverage, with a mean elimination half-life of approximately 6–8 hours.
Convenient Administration:
Flexible once-daily dosing with zero meal timing restrictions.
Reliable Pharmacokinetics:
Rapidly absorbed after oral administration, reaching median peak plasma concentrations (Tmax) within 1.5 hours (fasted) to 3.0 hours (fed). Food has no clinically significant or meaningful effect on overall exposure and absorption
Your Reasons For Choosing
Vonofast Medical
Severe Cutaneous Reactions:
Severe cutaneous adverse reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Erythema Multiforme, have been reported.
B12
Can be used for a Long-Term Use Continuous administration should be accompanied by regular clinical follow-up.
$10/20mg
Two concentrations suitable fro all casses
Symptomatic response to Vonofast therapy does not preclude the presence of gastric malignancy. Gastric cancer should be ruled out before initiating treatment where clinically indicated.
Elderly Patients:
Administer with caution and consider clinical monitoring, as elderly patients may have age-related declines in hepatic, renal,.
Hepatic Impairment:
Use with caution. Systemic exposure may increase due to reduced metabolic clearance in mild.
Renal Impairment:
Use with caution. Systemic exposure may increase due to reduced elimination of renal disease.
30°C
Storage Conditions: Store below 30°C. Protect from moisture and light by keeping the tablets in their original packaging. Keep out of the reach of children
Key Take-Homes
"Vonofast provides rapid, potent, and sustained acid suppression through innovative P-CAB technology, offering effective management of GERD, peptic ulcer disease, and Helicobacter pylori eradication."
First-line modern acid suppression option.
Fast and powerful acid control.
Effective for GERD and peptic ulcer disease.
Useful in H. pylori eradication therapy.
Once-daily convenient dosing.
Can be taken with or without food.
Clinical Advantages
vs. Traditional PPIs
Rapid Onset:
Provides fast onset of action, whereas traditional PPIs demonstrate a slower onset.
01
Feature
No Acid Activation Required:
Works directly without needing activation in an acidic environment, unlike traditional PPIs.
02
Feature
Strong and Consistent Acid Suppression:
Provides continuous, powerful acid suppression, whereas traditional PPIs offer variable suppression.
03
Feature
Less Dependent on Meals:
Can be taken with or without food, while traditional PPIs are often heavily affected by meal timing.
04
Feature
Sustained pH Control:
Delivers consistent and prolonged pH control compared to the less consistent pH control of standard PPIs.
05
Feature
Effective H. pylori Support:
Functions as a modern, reliable option for eradication regimens.
06
FeatureHave a question
Whether you require additional information about Vonofast® or have innovative ideas for a potential collaboration, we would love to hear from you. Please feel free to contact us with any questions, clinical inquiries, or partnership proposals. Our team is ready to connect and explore how we can work together to advance modern healthcare solutions.
VONOFAST®
//
Vonoprazan 10/20 mg
//
VONOFAST®
//
Vonoprazan 10/20 mg
//
VONOFAST®
//
VONOFAST®
//
Vonoprazan 10/20 mg
//
VONOFAST®
//
Vonoprazan 10/20 mg
//
VONOFAST®
//
"In my practice, I frequently treat patients suffering from severe reflux esophagitis. Vonofast has been an excellent addition to our treatment protocols. Because it provides rapid and sustained suppression of gastric acid, my patients consistently report quick relief from their symptoms. Furthermore, the convenience of taking it either with or without food significantly improves patient compliance with the prescribed regimen."
Gastroenterologist
Dr. Ramy Maeof"I regularly treat patients who require long-term non-steroidal anti-inflammatory drugs (NSAIDs), which unfortunately puts them at a high risk for developing ulcers. I often prescribe Vonofast 10 mg once daily as a preventative measure. It has proven highly effective in preventing the recurrence of gastric and duodenal ulcers associated with NSAID administration, giving me peace of mind that my patients' digestive health is protected."
General Practitioner
Dr. Ahmed Tariq"Vonofast is a highly reliable potassium-competitive acid blocker (P-CAB) that I frequently dispense for patients undergoing Helicobacter pylori eradication therapy. When used as an adjunct therapy alongside antibiotics like amoxicillin and clarithromycin, it plays a vital role in the treatment's success. I always make sure to counsel patients that the film-coated tablets must be swallowed whole and should not be chewed or crushed to ensure the medication works as intended."
Clinical Pharmacist
Emily Chen"Managing patients who experience a recurrent relapse of healed reflux esophagitis can be challenging, but maintenance therapy with Vonofast has yielded fantastic results in my clinic. The 10 mg daily dose is highly effective for long-term management up to 6 months. Its pharmacokinetic profile is impressive, generally reaching peak plasma concentrations within just a few hours after oral administration, which allows for prompt and dependable acid suppression."
Internal Medicine Specialist
Gamila HassanFeedback & Stories From Our Patients
4.9
Over All Rating
1.5k+
Clients Served
